SCHEMBL9195334

SCHEMBL9195334

CC(C)c1nc(-c2nccs2)cs1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SPHK2 Q9NRA0 1/20 0.50
▸ SPHK1 Q9NYA1 1/20 0.50
▸ CYP1A1 P04798 11/20 0.43
▸ CYP1A2 P05177 11/20 0.43
▸ CYP1B1 Q16678 11/20 0.43
▸ HSP90AA1 P07900 1/20 0.42
▸ ADORA3 P0DMS8 1/20 0.42
▸ ADORA2A P29274 1/20 0.42
▸ ADORA2B P29275 1/20 0.42
▸ ADORA1 P30542 1/20 0.42
▸ CFTR P13569 1/20 0.40
▸ NPY5R Q15761 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ PIK3CD O00329 1/20 0.38
▸ PIK3CA P42336 1/20 0.38
▸ PIK3CB P42338 1/20 0.38
▸ PIK3CG P48736 1/20 0.38
▸ SRC P12931 1/20 0.36
▸ ZAP70 P43403 1/20 0.36
▸ SYK P43405 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13093801 0.76 SPHK2 (0.58) SPHK2SPHK1CYP1A1CYP1A2CYP1B1
SCHEMBL21448899 0.74 TLR7 (0.44) PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL31374411 0.73 HSP90AA1 (0.56) SPHK2SPHK1CYP1A1CYP1A2CYP1B1
SCHEMBL11614665 0.73 SPHK2 (0.51) SPHK2SPHK1CYP1A1CYP1A2CYP1B1
SCHEMBL21926449 0.72 PIK3CD (0.39) PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL14558317 0.70 RAB9A (0.50) RAB9A
SCHEMBL1743410 0.70 CYP19A1 (0.56) CYP1A2HSP90AA1ADORA3RAB9A
SCHEMBL557653 0.69 — —
SCHEMBL9287048 0.69 PIK3CD (0.38) CYP1A2ADORA3RAB9APIK3CDPIK3CA
SCHEMBL9283691 0.69 RAB9A (0.49) SPHK2SPHK1CYP1A1CYP1A2CYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9024018-B2 3-substituted-8-substituted-3H-imidazo[5,1-d][1,2,3,5]tetrazin-4-one compounds and their use PHARMINOX LIMITED (GB) 2015-05-05 — — US disclosed
US-20120083513-A1 3-Substituted-8-Substituted-3H-Imidazo[5,1-d][1,2,3,5]tetrazin-4-one Compounds and Their Use PHARMINOX LIMITED (GB) 2012-04-05 — — US disclosed
US-20120083513-A1 3-Substituted-8-Substituted-3H-Imidazo[5,1-d][1,2,3,5]tetrazin-4-one Compounds and Their Use PHARMINOX LIMITED (GB) 2012-04-05 — — US disclosed
EP-0683772-A1 RETROVIRAL PROTEASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 1995-11-29 — — EP disclosed
EP-0683772-A4 RETROVIRAL PROTEASE INHIBITING COMPOUNDS. ABBOTT LAB (US) 1995-09-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083513-A1 3-Substituted-8-Substituted-3H-Imidazo[5,1-d][1,2,3,5]tetrazin-4-one Compounds and Their Use MKI67, CCNA1, CCNI SPHK2 4188/4885SPHK1 4278/4885CYP1A1 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback